The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit
later.
We apologize for any inconvenience caused
Impact of lamivudine-based antiretroviral therapy on hepatitis B virus(HBV)resistance mutations among HIV/HBV coinfected patients
Author(s): Wu Yasong, Deng Xiaojun, Zhang Weiwei, Lu Hongyan, Wei Feili, Yang Lian, Ma Ye, Liu Zhongfu, Zhang Fujie, National Center for AIDS, STD Control and Prevention, Chinese Center for Disease Control and Prevention, The Third People’s Hospital of Hengyang, Guangxi Center for Disease Control and Prevention, Beijing Institute of Hepatology, Department of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University
Pages: 407-
409+432
Year: 2016
Issue:
6
Journal: Chinese Journal of AIDS & STD
Keyword: HBV; HIV; Lamivudine(3TC); Drug resistance;
Abstract: Objective To evaluate the impact of lamivudine(3TC)based combination antiretroviral therapy(ART)on the hepatitis B viral(HBV)resistance mutations in HIV/HBV coinfected individuals.Methods 19 human immunodeficiency viral(HIV)/HBV coinfected individuals were included,who were treated with lamivudine based combination antiretroviral therapy and having HBV DNA>1000copies/mL at baseline.Mutational analysis of the RT-region was done by sequencing followed by genotyping.HBV resistance mutations at baseline and after 48 weeks of ART were analyzed.Results At baseline,no HBV resistance were detected in 5nave patients.Six of 14 experienced patients had HBV with lamivudine resistance mutations.After 48 weeks,none of nave patients and 8experienced patients was with HBV DNA higher than 1000copies/mL.Four patients developed new resistance mutations.Conclusion 3TC based ART is effective for HBV in HIV/HBV coinfected nave patients in short-term.TDF and 3TC based ART should be used for long term treatment for HIV/HBV coinfection.
Citations
No citation found